ATE423100T1 - Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden - Google Patents

Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden

Info

Publication number
ATE423100T1
ATE423100T1 AT06792301T AT06792301T ATE423100T1 AT E423100 T1 ATE423100 T1 AT E423100T1 AT 06792301 T AT06792301 T AT 06792301T AT 06792301 T AT06792301 T AT 06792301T AT E423100 T1 ATE423100 T1 AT E423100T1
Authority
AT
Austria
Prior art keywords
receptor
bind
quinoline compounds
new quinoline
compounds
Prior art date
Application number
AT06792301T
Other languages
English (en)
Inventor
Gerard Giblin
David Livermore
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE423100T1 publication Critical patent/ATE423100T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/40Nitrogen atoms attached in position 8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
AT06792301T 2005-09-28 2006-09-26 Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden ATE423100T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0519760.3A GB0519760D0 (en) 2005-09-28 2005-09-28 Novel compounds

Publications (1)

Publication Number Publication Date
ATE423100T1 true ATE423100T1 (de) 2009-03-15

Family

ID=35394902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06792301T ATE423100T1 (de) 2005-09-28 2006-09-26 Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden

Country Status (7)

Country Link
US (1) US20080249092A1 (de)
EP (1) EP1928833B1 (de)
JP (1) JP2009509997A (de)
AT (1) ATE423100T1 (de)
DE (1) DE602006005254D1 (de)
GB (1) GB0519760D0 (de)
WO (1) WO2007039220A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209872B1 (pl) 2002-03-27 2011-10-31 Glaxo Group Ltd Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
EP2508177A1 (de) 2007-12-12 2012-10-10 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2009140078A1 (en) * 2008-05-16 2009-11-19 The Procter & Gamble Company Treatment of lower urinary tract dysfunction with cb2-receptor-selective agonists
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
CN113264879B (zh) * 2021-05-27 2023-02-10 上海科技大学 一种基于喹诺酮结构的光控配体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000256323A (ja) * 1999-01-08 2000-09-19 Japan Tobacco Inc 2−オキソキノリン化合物及びその医薬用途
PL209872B1 (pl) * 2002-03-27 2011-10-31 Glaxo Group Ltd Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
DE602006005254D1 (de) 2009-04-02
JP2009509997A (ja) 2009-03-12
WO2007039220A1 (en) 2007-04-12
US20080249092A1 (en) 2008-10-09
GB0519760D0 (en) 2005-11-09
EP1928833B1 (de) 2009-02-18
EP1928833A1 (de) 2008-06-11

Similar Documents

Publication Publication Date Title
ATE423100T1 (de) Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
SE0203713D0 (sv) Novel compounds
ATE493397T1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
ATE345329T1 (de) Pyridinderivate als modulatoren des cb2-rezeptors
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
MXPA06014721A (es) Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico.
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
MY153719A (en) Prokineticin 1 receptor antagonists
TW200510301A (en) Novel compounds
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
CY1109854T1 (el) Παραγωγα αζαδικυκλο(3.1.0)εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
ATE479655T1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
MX2009003981A (es) Agentes moduladores del receptor de calcio.
DE602006015686D1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
MX2009012374A (es) Compuestos novedosos como ligandos del receptor de canabinoides.
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
ATE407119T1 (de) Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
ATE519755T1 (de) Modulatoren des vitamin-d-rezeptors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties